Switching medication products during the treatment of psychiatric illness

References

• Al Ameri, M. N., Whittaker, C., Tucker, A., Yaqoob, M., & Johnston, A. (2011). A survey to determine the views of renal transplant patients on generic substitution in the UK. Transplant International, 24, 770–779. doi:10.1111/j.1432-2277.2011.01268.x
   PubMed Web of Science ®Google Scholar
• Bartholow, M. 2013. Top 200 drugs of 2012; [cited September 12, 2017]. Available from: http://www.pharmacytimes.com/publications/issue/2013/july2013/top-200-drugs-of-2012
   Google Scholar
• Berg, M. J., Gross, R. A., Tomaszewski, K. J., Zingaro, W. M., & Haskins, L. S. (2008). Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology, 71, 525–530. doi:10.1212/01.wnl.0000319958.37502.8e
   PubMed Web of Science ®Google Scholar
• Blier, P. (2009). Generic substitution for psychotropic drugs. CNS Spectrums, 14, 1–7. doi:10.1017/S1092852900024706
   PubMed Web of Science ®Google Scholar
• Borgheini, G. (2003). The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clinical Therapeutics, 25, 1578–1592. doi:10.1016/S0149-2918(03)80157-1
   PubMed Web of Science ®Google Scholar
• Brady, L. S., & Insel, T. R. (2012). Translating discoveries into medicine: psychiatric drug development in 2011. Neuropsychopharmacology, 37, 281–283. doi:10.1038/npp.2011.106
   PubMed Web of Science ®Google Scholar
• Competition Bureau Canada. 2007. Canadian Generic Drug Sector Study. Gatineau, Quebec, Canada: Competition Bureau Canada.
   Google Scholar
• Colgan, S., Faasse, K., Martin, L. R., Stephens, M. H., Grey, A., & Petrie, K. J. (2015). Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. BMJ Open, 5, e008915 doi:10.1136/bmjopen-2015-008915
   PubMed Web of Science ®Google Scholar
• Contin, M., Alberghini, L., Candela, C., Benini, G., & Riva, R. (2016). Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens. Epilepsy Research, 122, 79–83. doi:10.1016/j.eplepsyres.2016.02.012
   PubMed Web of Science ®Google Scholar
• DelBello, M. P., Hanseman, D., Adler, C. M., Fleck, D. E., & Strakowski, S. M. (2007). Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. The American Journal of Psychiatry, 164, 582–590. doi:10.1176/ajp.2007.164.4.582
   PubMed Web of Science ®Google Scholar
• Desmarais, J. E., Beauclair, L., & Margolese, H. C. (2011). Switching from brand-name to generic psychotropic medications: a literature review. CNS Neuroscience & Therapeutics, 17, 750–760. doi:10.1111/j.1755-5949.2010.00210.x
   PubMed Web of Science ®Google Scholar
• DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33. doi:10.1016/j.jhealeco.2016.01.012
   PubMed Web of Science ®Google Scholar
• Drozdowska, A., & Hermanowski, T. (2016a). Exploring factors underlying the attitude of community pharmacists to generic substitution: a nationwide study from Poland. International Journal of Clinical Pharmacy, 38, 162–170. doi:10.1007/s11096-015-0227-8
   PubMed Web of Science ®Google Scholar
• Drozdowska, A., & Hermanowski, T. (2016b). Predictors of generic substitution: The role of psychological, sociodemographic, and contextual factors. Research in Social and Administrative Pharmacy, 12, 119–129. doi:10.1016/j.sapharm.2015.03.003
   PubMed Web of Science ®Google Scholar
• Druss, B. G., Marcus, S. C., Olfson, M., & Pincus, H. A. (2004). Listening to generic Prozac: winners, losers, and sideliners. Health Affairs (Project Hope), 23, 210–216. doi:10.1377/hlthaff.23.5.210
   PubMed Web of Science ®Google Scholar
• Dunne, S., Shannon, B., Dunne, C., & Cullen, W. (2014). Patient perceptions of generic medicines: a mixed-methods study. The Patient, 7, 177–185. doi:10.1007/s40271-013-0042-z
   PubMedGoogle Scholar
• El-Dahiyat, F., & Kayyali, R. (2013). Evaluating patients' perceptions regarding generic medicines in Jordan. Journal of Pharmaceutical Pharmacy and Practice, 6, 3 doi:10.1186/2052-3211-6-3
   Google Scholar
• Emanuele, E. (2011). Generic versus brand name drugs in psychopharmacology: a pharmacoeconomic perspective. Southern Medical Journal, 104, 715–716. doi:10.1097/SMJ.0b013e31822cf201
   PubMed Web of Science ®Google Scholar
• Erickson, S. C., Le, L., Ramsey, S. D., Solow, B. K., Zakharyan, A., Stockl, K. M., Harada, A.S., & Curtis, B. (2011). Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy. Epilepsia, 52, 1365–1371. doi:10.1111/j.1528-1167.2011.03130.x
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2010. Guideline on the investigation of bioequivalence; [cited January 18, 2018]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf
   Google Scholar
• Fadare, J. O., Adeoti, A. O., Desalu, O. O., Enwere, O. O., Makusidi, A. M., Ogunleye, O., Sunmonu, T. A., Truter, I., & Godman, B. (2016). The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians. Expert Review of Pharmacoeconomics & Outcomes Research, 16, 639–650. doi:10.1586/14737167.2016.1120673
   PubMed Web of Science ®Google Scholar
• Fallu, A., Dabouz, F., Furtado, M., Anand, L., & Katzman, M. A. (2016). A randomized, double-blind, cross-over, phase IV trial of oros-methylphenidate (CONCERTA®) and generic novo-methylphenidate ER-C (NOVO-generic)). Therapeutic Advances in Psychopharmacology, 6, 237–251. doi:10.1177/2045125316643674
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. 2004. Guidance for Industry. Statistical Approaches to Establishing Bioequivalence (2001). Available from https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070244.pdf
   Google Scholar
• Food and Drug Administration. 2014. Guidance for Industry. Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs—General Considerations. [cited October 1, 2018]. Available from https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM389370.pdf
   Google Scholar
• Food and Drug Administration. 2017. FDA Fact Sheet: What's involved in reviewing and approving generic drug applications?; [cited January 18, 2018]. Available from: https://www.fda.gov/downloads/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/GenericDrugs/UCM510852.pdf
   Google Scholar
• Fountoulakis, K. N., Grunze, H., Vieta, E., Young, A., Yatham, L., Blier, P., Kasper, S., & Moeller, H. J. (2017). The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines. The International Journal of Neuropsychopharmacology, 20, 180–195. doi:10.1093/ijnp/pyw109
   PubMed Web of Science ®Google Scholar
• Gagne, J. J., Kesselheim, A. S., Choudhry, N. K., Polinski, J. M., Hutchins, D., Matlin, O. S., Brennan, T.A., Avorn, J., & Shrank, W. H. (2015). Comparative effectiveness of generic versus brand-name antiepileptic medications. Epilepsy Behavior, 52, 14–18. doi:10.1016/j.yebeh.2015.08.014
   PubMed Web of Science ®Google Scholar
• Galgatte, U. C., Jamdade, V. R., Aute, P. P., & Chaudhari, P. D. (2014). Study on requirements of bioequivalence for registration of pharmaceutical products in USA, Europe and Canada. Saudi Pharmaceutical Journal, 22, 391–402. doi:10.1016/j.jsps.2013.05.001
   PubMed Web of Science ®Google Scholar
• Galgatte, U. C., Jamdade, V. R., Aute, P. P., & Chaudhari, P. D. (2013). Study on requirements of bioequivalence for registration of pharmaceutical products in India, South-Africa and Australia. American Journal of PharmTech Research, 3, 289–305.
   Google Scholar
• Health Canada. 2012a. Guidance document: conduct and analysis of comparative bioavailability studies; [cited September 18, 2017]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/bioavailability-bioequivalence/conduct-analysis-comparative.html#a
   Google Scholar
• Health Canada. 2012b. The safety and effectiveness of generic drugs; [cited January 18, 2018]. Available from: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/hl-vs/alt_formats/pdf/iyh-vsv/med/med-gen-eng.pdf
   Google Scholar
• Heikkila, R., Mantyselka, P., & Ahonen, R. (2011). Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland. Pharmacoepidemiology and Drug Safety, 20, 185–191. doi:10.1002/pds.2084
   PubMed Web of Science ®Google Scholar
• Helmers, S. L., Paradis, P. E., Manjunath, R., Duh, M. S., Lafeuille, M. H., Latremouille-Viau, D., Lefebvre,P., & Labiner, D. M. (2010). Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy Behavior, 18, 437–444. doi:10.1016/j.yebeh.2010.05.015
   PubMed Web of Science ®Google Scholar
• Hsu, C. W., Lee, S. Y., & Wang, L. J. (2018). Comparison of the effectiveness of brand-name and generic antipsychotic drugs for treating patients with schizophrenia in Taiwan. Schizophr Res, 193:107–113. doi:10.1016/j.schres.2017.06.020.
   Google Scholar
• Italiano, D., Bruno, A., Santoro, V., Lanza, G., Muscatello, M. R., Zoccali, R., & Spina, E. (2015). Generic olanzapine substitution in patients with schizophrenia: assessment of serum concentrations and therapeutic response after switching. Therapeutic Drug Monitoring, 37, 827–830. doi:10.1097/FTD.0000000000000211
   PubMed Web of Science ®Google Scholar
• Kessler, R. C., Aguilar-Gaxiola, S., Alonso, J., Chatterji, S., Lee, S., Ormel, J., Ustun, T.B., & Wang, P. S. (2009). The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiology and Psychiatric Sciences, 18, 23–33. doi:10.1017/S1121189X00001421
   Web of Science ®Google Scholar
• Kluznik, J. C., Walbek, N. H., Farnsworth, M. G., & Melstrom, K. (2001). Clinical effects of a randomized switch of patients from clozaril to generic clozapine. The Journal of Clinical Psychiatry, 62, 14–17. discussion 23-14.
   PubMed Web of Science ®Google Scholar
• Kobayashi, E., Karigome, H., Sakurada, T., Satoh, N., & Ueda, S. (2011). Patients' attitudes towards generic drug substitution in Japan. Health Policy, 99, 60–65. doi:10.1016/j.healthpol.2010.07.006
   PubMed Web of Science ®Google Scholar
• Labiner, D. M., Paradis, P. E., Manjunath, R., Duh, M. S., Lafeuille, M.-H., Latrémouille-Viau, D., Lefebvre, P., & Helmers, S. L. (2010). Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology, 74, 1566–1574. doi:10.1212/WNL.0b013e3181df091b
   PubMed Web of Science ®Google Scholar
• Lally, M. D., Kral, M. C., & Boan, A. D. (2016). Not all generic Concerta is created equal: comparison of OROS versus non-OROS for the treatment of ADHD. Clinical Pediatrics, 55, 1197–1201. doi:10.1177/0009922815611647
   PubMed Web of Science ®Google Scholar
• Lessing, C., Ashton, T., & Davis, P. (2015a). Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment. Administration and Policy in Mental Health, 42, 695–703. doi:10.1007/s10488-014-0606-9
   PubMed Web of Science ®Google Scholar
• Lessing, C., Ashton, T., & Davis, P. (2015b). An evaluation of health service impacts consequent to switching from brand to generic venlafaxine in New Zealand under conditions of price neutrality. Value Health, 18, 646–654. doi:10.1016/j.jval.2015.02.020
   PubMed Web of Science ®Google Scholar
• Lessing, C., Ashton, T., & Davis, P. B. (2015c). The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand. Journal of Primary Health Care, 7, 94–101.
   PubMed Web of Science ®Google Scholar
• MacDonald, J. T. (1987). Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology, 37, 1885 doi:10.1212/WNL.37.12.1885
   PubMed Web of Science ®Google Scholar
• Makus, K. G., & McCormick, J. (2007). Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clinical Therapeutics, 29, 334–341. doi:10.1016/j.clinthera.2007.02.005
   PubMed Web of Science ®Google Scholar
• Markoula, S., Chatzistefanidis, D., Gatzonis, S., Siatouni, A., Siarava, E., Verentzioti, A., Kyritsis, A.P., & Patsalos, P. N. (2017). Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting. Seizure, 48, 1–6. doi:10.1016/j.seizure.2017.03.012
   PubMed Web of Science ®Google Scholar
• Meyer, M. C. (2001). United States Food and Drug Administration requirements for approval of generic drug products. The Journal of Clinical Psychiatry, 62, 4–9. discussion 23-24.
   PubMed Web of Science ®Google Scholar
• Murawiec, S., Rajewska-Rager, A., Samochowiec, J., Kalinowska, S., Kurpisz, J., Krzyzanowska, J., Sienkiewicz-Jarosz, H., Kurkowska-Jastrzebska, I., Samochowiec, A., & Bienkowski, P. (2015). Pharmacy switch of antipsychotic medications: patient's perspective. Annals of General Psychiatry, 14, 31. doi:10.1186/s12991-015-0066-y
   PubMed Web of Science ®Google Scholar
• Nation, R. L., & Sansom, L. N. (1994). Bioequivalence requirements for generic products. Pharmacology Therapeutics, 62, 41–55. doi:10.1016/0163-7258(94)90004-3
   PubMed Web of Science ®Google Scholar
• Navarro-Artieda, R., Rejas-Gutierrez, J., Perez-Paramo, M., & Sicras-Mainar, A. (2016). Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: The effects of age and sex. Neurologia, Neurologia. 2018 Apr;33(3):141–153. doi:10.1016/j.nrl.2016.03.012. Epub 2016 Jun 16.
   PubMed Web of Science ®Google Scholar
• Nielsen, K. A., Dahl, M., Tommerup, E., & Wolf, P. (2008). Comparative daily profiles with different preparations of lamotrigine: a pilot investigation. Epilepsy & Behavior, 13, 127–130. doi:10.1016/j.yebeh.2008.02.020
   PubMed Web of Science ®Google Scholar
• Nixon, N. A., Khan, O. F., Imam, H., Tang, P. A., Monzon, J., Li, H., Sun, G., Ezeife, D., Parimi S., Dowden, S., & Tam, V.C. (2017). Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014. Cancer, 123, 4672–4679. doi:10.1002/cncr.30919
   PubMed Web of Science ®Google Scholar
• Oluboka, O., Stewart, S., Landry, S., & Adams, S. (2010). Does therapeutic equivalence follow bioequivalence? A randomized trial to assess clinical effects after switching from Clozaril to generic clozapine (gen-clozapine). Journal of Clinical Pharmacology, 50, 531–535. doi:10.1177/0091270009347871
   PubMed Web of Science ®Google Scholar
• Park-Wyllie, L., Van Stralen, J., Almagor, D., Dobson-Belaire, W., Charland, K., Smith, A., & Le Lorier, J. (2016). Medication Persistence, duration of treatment, and treatment-switching patterns among canadian patients taking once-daily extended-release methylphenidate medications for attention-deficit/hyperactivity disorder: a population-based retrospective cohort study. Clinical Therapeutics, 38, 1789–1802. doi:10.1016/j.clinthera.2016.07.001
   PubMed Web of Science ®Google Scholar
• Polard, E., Nowak, E., Happe, A., Biraben, A., & Oger, E., for the GENEPI Study Group (2015). Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study. Pharmacoepidemiology and Drug Safety, 24, 1161–1169. doi:10.1002/pds.3879
   PubMed Web of Science ®Google Scholar
• Rathe, J. O. (2015). The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting. Danish Medical Journal, 62, B5148.
   PubMed Web of Science ®Google Scholar
• Riordan, H. J., & Cutler, N. R. (2012). The death of CNS drug development: overstatement or omen? Journal of Clinical Studies, 3, 12–15.
   Google Scholar
• Schennach, R., Obermeier, M., Meyer, S., Jager, M., Schmauss, M., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L. G., Gaebel, W., Klosterkötter, J. Heuser, I. Maier, W, Lemke, M. R., Rüther, E., Klingberg, S., et al. 2012. Gaebel, W., Seemüller, F., Möller, H. J. & Ridele, M. (2012). Predictors of relapse in the year after hospital discharge among patients with schizophrenia. Psychiatric Services, 63, 87–90. doi:10.1176/appi.ps.201100084
   PubMed Web of Science ®Google Scholar
• Seoane-Vazquez, E., Rodriguez-Monguio, R., & Hansen, R. (2016). Interchangeability, safety and efficacy of modified-release drug formulations in the USA: the case of opioid and other nervous system drugs. Clinical Drug Investigation, 36, 281–292. doi:10.1007/s40261-015-0374-7
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar, A., Rejas-Gutierrez, J., & Navarro-Artieda, R. (2015). Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain. Clinicoecon omics & Outcomes Research, 7, 299–312. doi:10.2147/CEOR.S85756
   PubMed Web of Science ®Google Scholar
• Solem, C. T., Shelbaya, A., Wan, Y., Deshpande, C. G., Alvir, J., & Pappadopulos, E. (2016). Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data. Neuropsychiatric Disease and Treatment, 12, 2755–2764. doi:10.2147/NDT.S115094
   PubMed Web of Science ®Google Scholar
• Straka, R. J., Keohane, D. J., & Liu, L. Z. (2017). Potential clinical and economic impact of switching branded medications to generics. American Journal of Therapeutics, 24, e278–e289. doi:10.1097/MJT.0000000000000282
   PubMed Web of Science ®Google Scholar
• Talati, R., Scholle, J. M., Phung, O. P., Baker, E. L., Baker, W. L., Ashaye, A., Kluger, J., Coleman, C. I., & White, C. M. (2012). Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review. Pharmacotherapy, 32, 314–322. doi:10.1002/j.1875-9114.2012.01099.x
   PubMed Web of Science ®Google Scholar
• Toklu, H. Z., Dülger, G. A., Hıdıroğlu, S., Akici, A., Yetim, A., Gannemoğlu, H. M., & Güneş, H. (2012). Knowledge and attitudes of the pharmacists, prescribers and patients towards generic drug use in Istanbul - Turkey. Pharmacy Practice, 10, 199–206. doi:10.4321/S1886-36552012000400004
   PubMedGoogle Scholar
• Tothfalusi, L., & Endrenyi, L. (2013). Approvable generic carbamazepine formulations may not be bioequivalent in target patient populations. International Journal of Clinical Pharmacology and Therapeutics, 51, 525–528. doi:10.5414/CP201845
   PubMed Web of Science ®Google Scholar
• Toverud, E. L., Hartmann, K., & Hakonsen, H. (2015). A systematic review of physicians' and pharmacists' perspectives on generic drug use: what are the global challenges? Applied Health Economics and Health Policy, 13, 35–45. doi:10.1007/s40258-014-0145-2
   Web of Science ®Google Scholar
• Unterecker, S., Proft, F., Riederer, P., Lauer, M., Deckert, J., & Pfuhlmann, B. (2014). The comparison of brand-name and generic formulations of venlafaxine: a therapeutic drug monitoring analysis. Therapeutic Drug Monitoring, 36, 269–272. doi:10.1097/FTD.0000000000000008
   PubMed Web of Science ®Google Scholar
• Vari, M. S., Pinto, F., Mencaroni, E., Giudizioso, G., Minetti, C., La Neve, A., Francavilla T., Piccioli, M., Striano, S., del Gaudio, L. Tovo P., Striano, P., & Verrotti A. (2016). Safety of overnight switch from brand-name to generic levetiracetam. Clinical Drug Investigation, 36, 87–91. doi:10.1007/s40261-015-0351-1
   PubMed Web of Science ®Google Scholar
• Vlahiotis, A., Devine, S. T., Eichholz, J., & Kautzner, A. (2011). Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans. Journal of Managed Care Pharmacy, 17, 123–132.
   PubMed Web of Science ®Google Scholar
• Weissenfeld, J., Stock, S., Lungen, M., & Gerber, A. (2010). The nocebo effect: a reason for patients' non-adherence to generic substitution? Pharmazie, 65, 451–456. doi:10.1691/ph.2010.9749
   PubMed Web of Science ®Google Scholar
• Welty, T. E., Pickering, P. R., Hale, B. C., & Arazi, R. (1992). Loss of seizure control associated with generic substitution of carbamazepine. The Annals of Pharmacotherapy, 26, 775–777. doi:10.1177/106002809202600605
   PubMed Web of Science ®Google Scholar
• Woodcock, J., Khan, M., & Yu, L. X. (2012). Withdrawal of generic budeprion for nonbioequivalence. The New England Journal of Medicine, 367, 2463–2465. doi:10.1056/NEJMp1212969
   PubMed Web of Science ®Google Scholar
• Wu, E. Q., Yu, A. P., Lauzon, V., Ramakrishnan, K., Marynchenko, M., Ben-Hamadi, R., Blum, S., & Erder, M. H. (2011). Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. The Annals of Pharmacotherapy, 45, 441–451. doi:10.1345/aph.1P482
   PubMed Web of Science ®Google Scholar
• Yamada, M., & Welty, T. E. (2011). Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. The Annals of Pharmacotherapy, 45, 1406–1415. doi:10.1345/aph.1Q349
   PubMed Web of Science ®Google Scholar